SMTI trades 45.3% below Wall Street's consensus target of $32.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SMTI achieves its forward estimates and maintains a stable P/E multiple of 129.5x. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Sanara MedTech Inc. (SMTI) has a Wall Street consensus price target of $32.00, based on estimates from 3 covering analysts. With the stock currently trading at $21.47, this represents a potential upside of +45.3%. The company has a market capitalization of $197M.
Analyst price targets range from a low of $32.00 to a high of $32.00, representing a 0% spread in expectations. The median target of $32.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SMTI trades at a trailing P/E of -4.9x and forward P/E of 129.5x. Analysts expect EPS to grow +104.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVCRNovoCure Limited | $1.5B | $13.61 | $33.00 | +131.1% | Buy | — | 15 |
XTNTXtant Medical Holdings, Inc. | $61M | $0.44 | — | — | — | — | — |
MDXGMiMedx Group, Inc. | $545M | $3.67 | $10.00 | +172.5% | Buy | — | 15 |
KROSKeros Therapeutics, Inc. | $351M | $10.98 | $102.60 | +863.4% | Buy | — | 16 |
BLCOBausch + Lomb Corporation | $5.3B | $14.93 | $18.57 | +24.9% | Hold | 18.4x | 16 |
CWSTCasella Waste Systems, Inc. | $5.3B | $84.58 | $112.33 | +29.1% | Buy | 64.2x | 19 |
HROWHarrow Health, Inc. | $1.6B | $42.41 | $73.67 | +71.8% | Buy | 173.2x | 10 |
SRDXSurmodics, Inc. | $615M | $42.98 | $39.50 | -8.1% | Buy | — | 7 |
WSTWest Pharmaceutical Services, Inc. | $23.8B | $329.71 | $330.83 | +0.9% | Buy | 38.1x | 15 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
Quick answers to the most common questions about buying SMTI stock.
The consensus Wall Street price target for SMTI is $32, representing 45.3% upside from the current price of $21.47. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SMTI has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $32 implies 45.3% upside from current levels.
At a forward P/E of 129.5294x, SMTI trades at a premium valuation. The consensus price target of $32 (45.3% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $32 for SMTI, while the most conservative target is $32. The consensus of $32 represents the median expectation. These targets typically reflect 12-month expectations.
SMTI is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SMTI stock forecast based on 3 Wall Street analysts shows a consensus price target of $32, with estimates ranging from $32 (bear case) to $32 (bull case). The median consensus rating is "Buy".
SMTI trades at a forward P/E ratio of 129.5x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on SMTI, with a "Buy" consensus rating and $32 price target (45.3% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SMTI analyst price targets range from $32 to $32, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $32 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.